Predict your next investment

Singlera Genomics company logo
HEALTHCARE | Disease Diagnosis
singleragenomics.com

See what CB Insights has to offer

Stage

Series B - II | Alive

Total Raised

$232.95M

About Singlera Genomics

Singlera Genomics is a non-invasive genetic testing company. Singlera's main products and services include tumor diagnosis and personalized treatment, non-invasive prenatal diagnosis, pre-implantation genetic screening, and customized scientific research services.

Singlera Genomics Headquarter Location

8th Floor, Building 1, Lane 500, Furonghua Road, Pudong New Area

Shanghai, Shanghai,

China

+86-400-9204-888

Latest Singlera Genomics News

Samantha Du's Quan Capital, Lilly Asia back China's first big kidney play

May 10, 2021

Jason Mast Editor It’s been a good cou­ple years for kid­ney biotechs. Once a bar­ren field, it has since been filled with new com­pa­nies from blue-chip VC firms such as Arch , Ver­sant and Third Rock. Now some top-flight Chi­nese in­vestors are get­ting in on the ac­tion. Saman­tha Du Shang­hai-based Ale­bund Phar­ma­ceu­ti­cals an­nounced Mon­day that they raised a $60 mil­lion Se­ries B led by Quan Cap­i­tal, the VC firm from Zai Lab co-founder and CEO Saman­tha Du. Quan joined Lil­ly Asia Ven­tures, which in­cu­bat­ed the com­pa­ny be­gin­ning in 2018, among the new com­pa­ny’s most promi­nent back­ers. De­tails sur­round­ing Ale­bund are sparse — the biotech does not ap­pear to have a func­tion­ing web­site — but they said in a re­lease that they are go­ing af­ter the gamut of re­nal con­di­tions, from the ul­tra-ubiq­ui­tous chron­ic kid­ney dis­ease to the rare in­flam­ma­to­ry dis­ease IgA nephropa­thy. The com­pa­ny claims they are the first in Chi­na fo­cused ex­clu­sive­ly on de­vel­op­ing nov­el re­nal drugs and that their Se­ries B was the largest ever for a nephrol­o­gy-fo­cused Chi­nese com­pa­ny. They are led by Gavin Xia, who has been a ven­ture part­ner at Lil­ly Asia Ven­tures since 2018. He serves on the board of two oth­er Lil­ly-backed star­tups, the can­cer test­ing com­pa­ny Sin­glera Ge­nomics and the can­cer ther­a­peu­tics com­pa­ny Ab­bisko . Al­though the com­pa­ny has not di­vulged most of its drug can­di­dates, their lead pro­gram is al­ready in Phase II for hy­per­phos­phatemia, a con­di­tion where dan­ger­ous lev­els of phos­phate build up in the blood be­cause a pa­tient’s kid­ney isn’t fil­ter­ing the min­er­al prop­er­ly. Ac­cord­ing to a clin­i­cal­tri­als.gov reg­istry, they are try­ing to tack­le the dis­ease with VS-505, a mol­e­cule orig­i­nal­ly de­vel­oped by the small South Dako­ta-based biotech Vi­dasym. Ac­cord­ing to a 2016 pa­per in the British Jour­nal of Phar­ma­col­o­gy, VS-505 is de­rived from aca­cia tree sap and de­signed to bind to phos­phate in the blood with min­i­mal side ef­fects. Jin Tian, who leads clin­i­cal stud­ies at Vi­dasym, is al­so co-founder and CMO of Ale­bund. Ale­bund hopes to launch a piv­otal Phase III study next year. Ale­bund said they will al­so use the funds to help build their man­u­fac­tur­ing site. The com­pa­ny ar­gued in the re­lease that their work was par­tic­u­lar­ly im­por­tant now, as chron­ic kid­ney dis­ease has risen world­wide. They cit­ed epi­demi­o­log­i­cal da­ta that sug­gest as many 120 mil­lion peo­ple in Chi­na are liv­ing with CKD, the vast ma­jor­i­ty of them un­di­ag­nosed. AUTHOR Kyle Blankenship Managing Editor When Flagship Pioneering propped up a small research team back in 2017 to study a little-known circular form of RNA, it wasn’t exactly a high-profile project. But with mRNA providing the blueprint, that nascent biotech thinks it may have found the goldmine of all goldmines — and it’s all founded on a quixotic little molecule dubbed “eRNA.” Laronde, founded on science from Flagship general partner Avak Kahvejian and led by CEO-partner and former Vividion chief Diego Miralles, thinks eRNA could be the future of drugmaking, augmenting or replacing altogether standard drugs. On Monday, the biotech formally launched with a $50 million check from Flagship and some huge ambitions despite its relatively meager pocketbook. Keep reading Endpoints with a free subscription Unlock this story instantly and join 104,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP John Carroll Editor & Founder Omid Farokhzad is jumping into the SPAC game, and he’s going in with one of the most experienced teams we’ve seen in biotech — an unusual blend of financial and industry insiders, deep-pocket investors and a certain billionaire scientist who has played a longtime support role for his former student. The former Harvard professor had been co-founder for a string of biotechs before deciding to devote himself to a new role as CEO of Seer —where the big idea these past 2 years-plus has been to shift away from genomics in favor of a a proteomics platform that is doing some population-wide explorations, building a mountain of data that can be probed with machine learning tech in search of insights into diseases that can be used to develop liquid biopsy products for early-stage diagnosis. Keep reading Endpoints with a free subscription Unlock this story instantly and join 104,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Jason Mast Editor Ionis announced on Friday they would kill an early-stage effort for cystic fibrosis, dropping out of a medium-profile race with two other RNA-focused biotechs and adding a second black mark in what’s already been a tough year for their pipeline. Ionis chief development officer Richard Geary told investors on their Q1 earnings call that they were cutting the Phase I/II CF program, known as Ionis-Enac-2.5-Rx, after a long-term toxicology in animals turned up concerning results. Geary said they could have worked through the potential safety issue, but that it would have set back their timelines considerably. Neither he nor CEO Brett Monia elaborated on what the issue was. Keep reading Endpoints with a free subscription Unlock this story instantly and join 104,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Amber Tong Senior Editor Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here . The email version of Endpoints Weekly has now crossed the 10,000 subscriber mark. Thanks for being the first readers to sign up. Your feedback and thoughts are always welcome — my email is just below. Keep reading Endpoints with a free subscription Unlock this story instantly and join 104,900+ biopharma pros reading Endpoints daily — and it's free. SIGN UP LOG IN

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Singlera Genomics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Singlera Genomics in 1 CB Insights research brief, most recently on Oct 10, 2019.

Expert Collections containing Singlera Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Singlera Genomics is included in 5 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

D

Digital Health

12,723 items

M

Medical Devices

7,891 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,213 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Singlera Genomics Patents

Singlera Genomics has filed 4 patents.

The 3 most popular patent topics include:

  • Genetics
  • Molecular biology
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/18/2018

Transcription factors, Molecular biology, DNA, Bioinformatics, Gene expression

Application

Application Date

4/18/2018

Grant Date

Title

Related Topics

Transcription factors, Molecular biology, DNA, Bioinformatics, Gene expression

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.